Skip to content
Menu
About
Platform
Programs
News
Careers
Contact
News
News Release
Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to Find Tailored Treatment for the Complex Rare Disease
Announcement
Proof of concept in preclinical models for the use of QPCTL inhibition
News Release
Scenic Biotech Announces $31 Million Financing to Progress Pipeline of Genetic Modifiers in Cancer and Rare Diseases
Coverage
Biocentury features an emerging company profile on Scenic Biotech
Announcement
Sebastian Nijman presenting at BioTrinity 2021
Announcement
Scenic Biotech and Genentech expand their Genetic Modifier Partnership
News Release
Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman
Announcement
Ton Schumacher, member of Scenic’s Scientific Advisory Board has been awarded the Jeantet-Collen Prize for Translational Medicine
Coverage
Scenic’s Chief Scientific Officer Sebastian Nijman explains why genetic modifiers are an untapped source of drug targets
News Release
Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech
Announcement
Scenic founders publish paper in Science Signaling
News Release
Scenic Biotech Appoints Oscar Izeboud as Chief Executive Officer